Search

Displaying results 1951 - 1960 of 4539 in total
  1. Drug

    Roquinimex

    go.drugbank.com/drugs/DB11366
    Experimental

    Its effects are suggested to increase the activity of NK cells and macrophage cytotoxicity. Additionally, roquinimex is known to inhibit angiogenesis and to decrease the synthesis of TNF alpha.

  2. Drug

    Felodipine

    go.drugbank.com/drugs/DB01023
    Approved

    It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. … By inhibiting the influx of calcium in smooth muscle cells, felodipine prevents calcium-dependent myocyte contraction and vasoconstriction.

  3. Drug

    Elivaldogene autotemcel

    go.drugbank.com/drugs/DB16746
    Approved

    [L40298] In September 2022, Skysona was approved by the FDA.[L43247] … [A243691] Elivaldogene autotemcel works by delivering genes into the patient's body to produce functional ALDPs.

  4. Drug

    Cimlanod

    go.drugbank.com/drugs/DB14983
    Investigational

    Cimlanod is under investigation in clinical trial NCT02819271 (A First-in-Human Study of the Safety of Single Continuous Intravenous (IV) Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers)

  5. Drug

    Ursodeoxycholic acid

    go.drugbank.com/drugs/DB01586
    ApprovedInvestigational

    [A256272] UDCA works by replacing the hydrophobic or more toxic bile acids from the bile acid pool.[A256272] … [A256272] UDCA was first approved by the FDA in 1987 for dissolution of gallstones and for primary biliary cirrhosis in 1996.

  6. Drug

    Etripamil

    go.drugbank.com/drugs/DB12605
    ApprovedInvestigational

    [A275243, A275248] The nasal formulation of etripamil was first approved by the FDA on December 12, 2025 for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT

  7. Drug

    Valrubicin

    go.drugbank.com/drugs/DB00385
    Approved

    Used in the treatment of the bladder cancer, valrubicin is administered by direct infusion into the bladder.

  8. Drug

    Oxaliplatin

    go.drugbank.com/drugs/DB00526
    ApprovedInvestigational

    [A797] Oxaliplatin was approved by the FDA on January 9, 2004 and is currently marketed by Sanofi-Aventis under the trademark Eloxatin®.[L47316] … [A797] However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties.

  9. Drug

    Forigerimod

    go.drugbank.com/drugs/DB12490
    Investigational

    Forigerimod is under investigation for the treatment of Lupus Erythematosus, Systemic.

    Categories: Ribonucleoprotein, U1 Small Nuclear
  10. Drug

    Tirbanibulin

    go.drugbank.com/drugs/DB06137
    ApprovedInvestigational

    [A225726] On December 14, 2020, tirbanibulin was approved by the FDA for the topical treatment of actinic keratosis on the face or scalp. It is marketed under the brand name Klisyri. … [L27806] Actinic keratosis is a chronic condition characterized by lesions, which can potentially transform into invasive squamous cell carcinoma with a risk of 1% over 10 years.